Kanghong Pharmaceuticals: Subsidiary received notification of drug clinical trial approval.

On May 19, Kanghong Pharmaceutical announced that its wholly-owned subsidiary Kanghong Biologics has received the "Notice of Drug Clinical Trial Approval" issued by the National Medical Products Administration, approving the clinical trial of KH812 intraocular injection solution for the clinical indication of neovascular age-related macular degeneration.